Comparison of nonhydrolysis and hydrolysis methods for the determination of buprenorphine metabolites in urine by liquid chromatography-tandem mass spectrometry

Journal of Analytical Toxicology

Volumn 32, Issue 9, 2008, Pages 744-753

  Al Asmari, Ahmed I ^a   Anderson, Robert A ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIUM FORMATE; BUPRENORPHINE; BUPRENORPHINE 3 GLUCURONIDE; NORBUPRENORPHINE; NORBUPRENORPHINE 3 GLUCURONIDE; UNCLASSIFIED DRUG; BETA GLUCURONIDASE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; NARCOTIC ANTAGONIST;

CONFERENCE PAPER; ELECTROSPRAY MASS SPECTROMETRY; HYDROLYSIS; LIQUID CHROMATOGRAPHY; PH; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; URINALYSIS; VALIDATION STUDY; ANIMAL; ARTICLE; CHEMISTRY; COMPARATIVE STUDY; HELIX (SNAIL); HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; REGRESSION ANALYSIS; REPRODUCIBILITY; STANDARD; URINE;

ANIMALS; BUPRENORPHINE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLUCURONIDASE; HELIX (SNAILS); HUMANS; INDICATORS AND REAGENTS; NARCOTIC ANTAGONISTS; REFERENCE STANDARDS; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 57349198259     PISSN: 01464760     EISSN: 01464760     Source Type: Journal    
DOI: 10.1093/jat/32.9.744     Document Type: Conference Paper

References (46)

1. A.C. Moffat, M.D. Ossleton, B. Widdop, and L.Y. Galichet. Clarke's Analysis of Drugs and Poisons, 3rd ed. Pharmaceutical Press, London, U.K., 2004, pp 723-725.
2. R.C. Baselt and R.H. Cravey. Disposition of Toxic Drugs and Chemicals in Man, 6th ed. Biomedical Publications, Foster City, CA, 2004, pp 129-131.
3. O.H. Drummer and M. Odell. Forensic Pharmacology Drugs of Abuse. Hodder Arnold, London, U.K., 2001, pp 219-265.
4. K. Bentley. "The morphine alkaloids". In The Alkaloids. R.F. Manske, Ed. Academic Press, New York, NY, 1971 pp. 75-120.
5. A. Cowan, J.W. Lewis, and I.R. Macfarlane. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br. J. Pharmacol. 60(4): 537-545 (1977).
6. A. Elkader and B. Sproule. Buprenorphine: clinical pharmacokinetics in the treatment of opioid dependence. Clin. Pharmacokinet. 44(7): 661-680 (2005).
7. R.E. Johnson, H.E. Jones, D.R. Jasinski, D.S. Svikis, N.A. Haug, L.M. Jansson, W.B. Kissin, G. Alpan, M.E. Lantz, E.J. Cone, D.G. Wilkins, A.S. Golden, G.R. Huggins, and B.M. Lester. Buprenorphine treatment of pregnant opioid-dependent women: maternal and neonatal outcomes. Drug Alcohol Depend. 63(1): 97-103 (2001).
8. A. Polettini and M.A. Huestis. Simultaneous determination of buprenorphine, norbuprenorphine, and buprenorphine-glucuronide in plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Biomed. Sci. Appl. 754(2): 447-459 (2001).
9. A. Tracqui, P. Kintz, and B. Ludes. Buprenorphine-related deaths among drug addicts in France: a report on 20 fatalities. J. Anal. Toxicol. 22(6): 430-434 (1998).
10. P. Kintz. A new series of 13 buprenorphine-related deaths. Clin. Biochem. 35(7): 513-516 (2002).
11. W. Huang, D.E. Moody, and E.F. McCance-Katz. The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography- electrospray ionization-tandem mass spectrometry. Ther. Drug Monit. 28(2): 245-251 (2006).
12. E.J. Cone, C.W. Gorodetzky, D. Yousefnejad, W.F. Buchwald, and R.E. Johnson. The metabolism and excretion of buprenorphine in humans. Drug Metab. Dispos. 12(5): 577-581(1984).
13. A.J. Bartlett, J.G. Lloyd-Jones, M.J. Rance, I.R. Flockhart, G.J. Dockray, M.R. Bennett, and R.A. Moore. The radioimmunoassay of buprenorphine. Eur. J. Clin. Pharmacol. 18(4): 339-345 (1980).
14. M. Bottcher and O. Beck. Evaluation of buprenorphine CEDIA assay versus GC-MS and ELISA using urine samples from patients in substitution treatment. J. Anal. Toxicol. 29(8): 769-776 (2005).
15. A. Cirimele, P. Kintz, S. Lohner, and B. Ludes. Enzyme immunoassay validation for the detection of buprenorphine in urine. J. Anal. Toxicol. 27(2): 103-105 (2003).
16. E.I. Miller, H.J. Torrance, and J.S. Oliver. Validation of the Immunalysis microplate ELISA for the detection of buprenorphine and its metabolite norbuprenorphine in urine. J. Anal Toxicol. 30(2): 115-119 (2006).
17. S. Gopal, T.B. Tzeng, and A. Cowan. Development and validation of a sensitive analytical method for the simultaneous determination of buprenorphine and norbuprenorphine in human plasma. Eur. J. Pharmaceut. Biopharm. 51(2): 147-151 (2001).
18. D.E. Moody, J.D. Laycock, A.C. Spanbauer, D.J. Crouch, R.L. Foltz, J.L. Josephs, L. Amass, and W.K. Bickel. Determination of buprenorphine in human plasma by gas chromatography-positive ion chemical ionization mass spectrometry and liquid chromatography-tandem mass spectrometry. J. Anal. Toxicol. 21(6): 406-414 (1997).
19. M.A. ElSohly, W. Gul, S. Feng, and T.P. Murphy. Hydrolysis of conjugated metabolites of buprenorphine II. The quantitative enzymatic hydrolysis of norbuprenorphine-3-beta-D-glucuronide in human urine. J. Anal. Toxicol. 29(6): 570-573 (2005).
20. Y. Blom, U. Bondesson, and E. Anggard. Analysis of buprenorphine and its N-dealkylated metabolite in plasma and urine by selected-ion monitoring. J. Chromatogr. 338(1): 89-98 (1985).
21. I.R. Tebbett. Analysis of buprenorphine by high-performance liquid chromatography. J. Chromatogr. 347(3): 411-413 (1985).
22. E.R. Garrett and T. Gurkan. Pharmacokinetics of morphine and its surrogates I: comparisons of sensitive assays of morphine in biological fluids and application to morphine pharmacokinetics in the dog. J. Pharm. Sci. 67(11): 1512-1517 (1978).
23. L. Debrabandere, M. Van Boven, and P. Daenens. High-performance liquid chromatography with electrochemical detection of buprenorphine and its major metabolite in urine. J. Chromatogr. 564(2): 557-566 (1991).
24. H. Hoja, P. Marquet, B. Verneuil, H. Lotfi, J.L. Dupuy, and G. Lachatre. Determination of buprenorphine and norbuprenorphine in whole blood by liquid chromatography-mass spectrometry. J. Anal. Toxicol. 21(2): 160-165 (1997).
25. A.I. Al-Asmari and R.A. Anderson. Method for quantification of opioids and their metabolites in autopsy blood by liquid chromatography-tandem mass spectrometry. J. Anal. Toxicol. 31(7): 394-408 (2007).
26. A. Ceccato, R. Klinkenberg, P. Hubert, and B. Streel. Sensitive determination of buprenorphine and its N-dealkylated metabolite norbuprenorphine in human plasma by liquid chromatography coupled to tandem mass spectrometry. J. Pharm. Biomed. Anal. 32(4-5): 619-631 (2003).
27. R. Kronstrand, T.G. Selden, and M. Josefsson. Analysis of buprenorphine, norbuprenorphine, and their glucuronides in urine by liquid chromatography-mass spectrometry. J. Anal. Toxicol. 27(7): 464-470 (2003).
28. C.M. Murphy and M.A. Huestis. Liquid chromatographic-electrospray ionization tandem mass spectrometric analysis for the quantification of buprenorphine, norbuprenorphine, buprenorphine-3-beta-D-glucuronide and norbuprenorphine-3-beta-D-glucuronide in human plasma. J. Mass Spectrom. 40(1): 70-74 (2005).
29. E.J. Fox, V.A. Tetlow, and K.R. Allen. Quantitative analysis of buprenorphine and norbuprenorphine in urine using liquid chromatography tandem mass spectrometry. J. Anal. Toxicol. 30(4): 238-244 (2006).
30. S. Hegstad, H.Z. Khiabani, E.L. Oiestad, T. Berg, and A.S. Christophersen. Rapid quantification of buprenorphine-glucuronide and norbuprenorphine-glucuronide in human urine by LC-MS-MS. J. Anal. Toxicol. 31(4): 214-219 (2007).
31. S. Feng, M.A. ElSohly, and D.T. Duckworth. Hydrolysis of conjugated metabolites of buprenorphine. I. The quantitative enzymatic hydrolysis of buprenorphine-3-beta-D-glucuronide in human urine. J. Anal. Toxicol. 25(7): 589-593 (2001).
32. R. Kaushik, B. Levine, and W.R. LaCourse. A brief review: HPLC methods to directly detect drug glucuronides in biological matrices (Part I). Anal. Chim. Acta 556(2): 255-266 (2006).
33. P. Wang, J.A. Stone, K.H. Chen, S.F. Gross, C.A. Haller, and A.H. Wu. Incomplete recovery of prescription opioids in urine using enzymatic hydrolysis of glucuronide metabolites. J. Anal. Toxicol. 30(8): 570-575 (2006).
34. B.K. Matuszewski, M.L. Constanzer, and C.M. Chavez-Eng. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS-MS. Anal. Chem. 75(13): 3019-3030 (2003).
35. H.H. Maurer. Advances in analytical toxicology: the current role of liquid chromatography-mass spectrometry in drug quantification in blood and oral fluid. Anal. Bioanal. Chem. 381(1): 110-118 (2005).
36. G. Hopfgartner and E. Bourgogne. Quantitative high-throughput analysis of drugs in biological matrices by mass spectrometry. Mass Spectrom. Rev. 22(3): 195-214 (2003).
37. W.M. Niessen, P. Manini, and R. Andreoli. Matrix effects in quantitative pesticide analysis using liquid chromatography-mass spectrometry. Mass Spectrom. Rev. 25(6): 881-899 (2006).
38. J.N. Miller and J C. Miller. Statistics and Chemometrics for Analytical Chemistry. Pearson Prentice Hall, Harlow, Essex, U.K., 2005, pp 126-131.
39. F.T. Peters, O.H. Drummer, and F. Musshoff. Validation of new methods. Forensic Sci. Int. 165(2-3): 216-224 (2007).
40. J.X. Shen, R.J. Motyka, J.P. Roach, and R.N. Hayes. Minimization of ion suppression in LC-MS-MS analysis through the application of strong cation exchange solid-phase extraction (SCX-SPE). J. Pharm. Biomed. Anal. 37(2): 359-367 (2005).
41. E. Chambers, D.M. Wagrowski-Diehl, Z. Lu, and J.R. Mazzeo. Systematic and comprehensive strategy for reducing matrix effects in LC-MS-MS analyses. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 852(1-2): 22-34 (2007).
42. N.J. Bouwmeester, B.J. Anderson, D. Tibboel, and N.H. Holford. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children. Br. J. Anaesth. 92(2): 208-217 (2004).
43. J.C. Van de Steene, K.A. Mortier, and W.E. Lambert. Tackling matrix effects during development of a liquid chromatographic-electrospray ionisation tandem mass spectrometric analysis of nine basic pharmaceuticals in aqueous environmental samples. J. Chromatogr. A 1123(1): 71-81 (2006).
44. T. Benijts, R. Dams, W. Lambert, and A. De Leenheer. Countering matrix effects in environmental liquid chromatography-electrospray ionization tandem mass spectrometry water analysis for endocrine disrupting chemicals. J. Chromatogr. A 1029(1-2): 153-159 (2004).
45. S. George, C. George, and M. Chauhan. The development and application of a rapid gas chromatography-mass spectrometry method to monitor buprenorphine withdrawal protocols. Forensic Sci. Int. 143(2-3): 121-125 (2004).
46. R.H. Liu and D.E. Gadzala. Handbook of Drug Analysis: Applications in Forensic and Clinical Laboratories. American Chemical Society, Washington, D.C, 1997, p 22.